Literature DB >> 12806198

Efficacy of SPIO-MR imaging in the diagnosis of liver metastases from colorectal carcinomas.

Tomohisa Furuhata1, Kenji Okita, Tetsuhiro Tsuruma, Fumitake Hata, Yasutoshi Kimura, Tadashi Katsuramaki, Mitsuhiro Mukaiya, Naoki Hirokawa, Takeshi Ichimura, Naoya Yama, Kazumitsu Koito, Kazuaki Sasaki, Koichi Hirata.   

Abstract

AIM: To determine whether superparamagnetic iron oxide-enhanced magnetic resonance imaging (SPIO-MRI) could replace intravenous contrast-enhanced spiral CT (iv-CT) and spiral CT during arterial portography (CTAP) combined with spiral CT hepatic angiography (CTHA) in the diagnosis of liver metastases from colorectal carcinomas.
METHODS: Twenty-six adult patients with liver metastases were studied preoperatively by means of iv-CT, CTAP/CTHA, and SPIO-MRI. Preoperative diagnoses using iv-CT, CTAP/CTHA, and SPIO-MRI were compared with intraoperative and pathological findings in resected specimens. The gold standard for the lesions that were resected was histological examination. Intraoperative findings represented the gold standard for lesions that were not resected.
RESULTS: Twenty-six patients were found to have a total number of 43 liver metastases. The sensitivities of iv-CT, CTAP/CTHA, and SPIO-MRI were 74.4, 100, and 90.7%, respectively. SPIO-MRI was significantly superior to iv-CT (p < 0.05). The positive predictive values of iv-CT, CTAP/CTHA, and SPIO-MRI were 97.0, 91.5, and 100%, respectively. CTAP/CTHA yielded four false-positive lesions. In contrast, we detected no false-positive findings using SPIO-MRI.
CONCLUSIONS: These results suggest that SPIO-MRI might not completely replace CTAP/CTHA, but could replace iv-CT in the diagnosis of liver metastases from colorectal carcinomas. It is thought that SPIO-MRI is a promising imaging modality for diagnosing liver metastases in patients with colorectal carcinoma because of its relatively high sensitivity and extremely high specificity. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2003        PMID: 12806198     DOI: 10.1159/000071758

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  6 in total

1.  Assessment of liver metastases from colorectal adenocarcinoma following chemotherapy: SPIO-MRI versus FDG-PET/CT.

Authors:  L Bacigalupo; S Aufort; M C Eberlé; E Assenat; M Ychou; B Gallix
Journal:  Radiol Med       Date:  2010-06-23       Impact factor: 3.469

2.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.

Authors:  V O Chan; J P Das; J F Gerstenmaier; J Geoghegan; R G Gibney; C D Collins; S J Skehan; D E Malone
Journal:  Ir J Med Sci       Date:  2012-03-17       Impact factor: 1.568

3.  Magnetic resonance imaging of the liver: New imaging strategies for evaluating focal liver lesions.

Authors:  Kenneth Coenegrachts
Journal:  World J Radiol       Date:  2009-12-31

4.  Appearances of colorectal hepatic metastases at diffusion-weighted MRI compared with histopathology: initial observations.

Authors:  E D Scurr; D J Collins; L Temple; N Karanjia; M O Leach; D-M Koh
Journal:  Br J Radiol       Date:  2011-01-11       Impact factor: 3.039

Review 5.  New MR techniques for the detection of liver metastases.

Authors:  J Ward
Journal:  Cancer Imaging       Date:  2006-05-31       Impact factor: 3.909

6.  Is neoadjuvant chemotherapy necessary for patients with initially resectable colorectal liver metastases in the era of effective chemotherapy?

Authors:  Sang-Yong Son; Nam-Joon Yi; Geun Hong; Hyeyoung Kim; Min Su Park; Young Rok Choi; Kyung-Suk Suh; Duck-Woo Kim; Seung-Yong Jeong; Kyu-Joo Park; Jae-Gahb Park; Kuhn-Uk Lee
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2011-12-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.